Minerva Neurosciences
$5.6
63
-$0.43-7.05% Wednesday 20:00
Statistics
Day High
6.16
Day Low
5.59
52W High
12.46
52W Low
1.15
Volume
164,147
Avg. Volume
213,529
Mkt Cap
39.16M
P/E Ratio
2.84
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6MayExpected
Expected EPS
-0.1303
Actual EPS
N/A
Financials
-Profit Margin
Profitable0Revenue
2.88MNet Income
Analyst Ratings
$7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 0%
Hold 100%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NERV. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Alkermes
ALKS
Mkt Cap5.07B
BridgeBio Pharma
BBIO
Mkt Cap12.07B
Biogen
BIIB
Mkt Cap22.63B
AMGEN
AMGN
Mkt Cap160.66B
Insmed
INSM
Mkt Cap40.44B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Palatin Technologies
PTN
Mkt Cap2.45M
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Dr. Remy Luthringer Ph.D.
Employees
8
Country
US
ISIN
US6033802058
Listings
0 Comments
Share your thoughts
FAQ
What is Minerva Neurosciences stock price today?▼
The current price of NERV is $5.6 USD — it has decreased by -7.05% in the past 24 hours. Watch Minerva Neurosciences stock price performance more closely on the chart.
What is Minerva Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Minerva Neurosciences stocks are traded under the ticker NERV.
Is Minerva Neurosciences stock price growing?▼
NERV stock has fallen by -8.79% compared to the previous week, the month change is a -18.84% fall, over the last year Minerva Neurosciences has showed a +247.83% increase.
What is Minerva Neurosciences market cap?▼
Today Minerva Neurosciences has the market capitalization of 39.16M
When is the next Minerva Neurosciences earnings date?▼
Minerva Neurosciences is going to release the next earnings report on May 06, 2026.
What were Minerva Neurosciences earnings last quarter?▼
NERV earnings for the last quarter are -0.64 USD per share, whereas the estimation was -0.3 USD resulting in a -111.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Minerva Neurosciences revenue for the last year?▼
Minerva Neurosciences revenue for the last year amounts to 0 USD.
What is Minerva Neurosciences net income for the last year?▼
NERV net income for the last year is 2.88M USD.
How many employees does Minerva Neurosciences have?▼
As of April 02, 2026, the company has 8 employees.
In which sector is Minerva Neurosciences located?▼
Minerva Neurosciences operates in the Health Care sector.
When did Minerva Neurosciences complete a stock split?▼
The last stock split for Minerva Neurosciences was on June 21, 2022 with a ratio of 1:8.
Where is Minerva Neurosciences headquartered?▼
Minerva Neurosciences is headquartered in Burlington, US.